The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis

Conclusion: Improving conditions in the patient's room, choosing pre-emptive antifungal treatment instead of empirical antifungal treatment, switching to tablet form of VOR after initiation of its intravenous form, secondary prophylaxis with VOR against invasive aspergillosis, primary prophylaxis with POS in high-risk patients, and choosing less L-AmB as being an alternative to other antifungal drugs, may reduce expenditures related to the use of antifungal drugs in the treatment of invasive fungal infections during febrile neutropenic episodes of patients with hematological malignancies. Keywords: hematological malignancies, invasive fungal infection, expenditure, antifungal drug, neutropenia
Source: ClinicoEconomics and Outcomes Research - Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research